Last update 04 Nov 2024

Lisinopril

Last update 04 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryLisinopril is a type of medication known as an angiotensin-converting enzyme (ACE) inhibitor that is frequently prescribed for the management of hypertension, heart failure, and other cardiovascular conditions. By preventing the conversion of angiotensin I to angiotensin II, a hormone that causes blood vessels to constrict, lisinopril helps to reduce blood pressure. The medication is available in oral formulations and generally well-tolerated by patients. Nonetheless, side effects, such as cough, dizziness, and hypotension, may occur. As a researcher, it is noteworthy that ongoing investigations into the potential benefits of lisinopril for the treatment of conditions like diabetic nephropathy and migraines have shown encouraging results in preclinical and clinical studies.

Drug Type

Small molecule drug

Synonyms

(S)-1-(N(2)-(1-Carboxy-3-phenylpropyl)-L-lysyl)-L-proline, [N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline, Lisinopril (INN)

+ [26]

Target

ACE

Mechanism

ACE inhibitors(Angiotensin-converting enzyme inhibitors)

Therapeutic Areas

Cardiovascular DiseasesUrogenital Diseases

Active Indication

Chronic heart failureEssential HypertensionHypertension, Renovascular+ [3]

Inactive Indication

Polycystic Kidney, Autosomal Dominant

Originator Organization

Merck Sharp & Dohme Corp.

AstraZeneca PLC

Active Organization

Azurity Pharmaceuticals, Inc.

Kyowa Pharmaceutical Industry Co., Ltd.

TWi Pharmaceuticals, Inc.

+ [3]

Inactive Organization

Merck Research Laboratories Massachusetts LLC

Alvogen, Inc.

Drug Highest PhaseApproved

First Approval Date

US (29 Dec 1987),

Acute myocardial infarctionHeart FailureHypertension

Regulation-

Structure

Molecular FormulaC21H35N3O7

InChIKeyCZRQXSDBMCMPNJ-ZUIPZQNBSA-N

CAS Registry83915-83-7

114

Clinical Trials associated with Lisinopril

NCT03201939 / SuspendedPhase 2IIT

Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria

In this study, the Investigators plan to determine the optimal means to prevent or slow the progression of kidney disease among genetically at-risk northern Nigerian HIV-infected adults. Based on data from studies of diabetic kidney disease that used medications that block the renin angiotensin aldosterone system (RAAS), we plan to evaluate whether or not RAAS inhibition (using a widely available medication that blocks RAAS) in HIV-infected adults produces similarly promising results.

Start Date01 Nov 2024

Sponsor / Collaborator

Vanderbilt University Medical Center

[+3]

NCT06372470 / RecruitingNot Applicable

Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment

A pragmatic observational proof-of-concept study which aims to determine the feasibility of a remote titration clinic, assisted by home blood pressure monitoring and digital solutions, and assess its impact on real-world outcomes. By incorporating home blood pressure monitoring, the study seeks to offer a promising solution for personalised drug titration and self-management, potentially enhancing patient outcomes while optimising Zestril utilisation

Start Date15 Apr 2024

Sponsor / Collaborator

Closed Loop Medicine Ltd.Startup

[+1]

NCT05530655 / RecruitingEarly Phase 1IIT

A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.

Start Date20 Feb 2024

Sponsor / Collaborator

University of Rochester

[+1]

100 Clinical Results associated with Lisinopril

100 Translational Medicine associated with Lisinopril

100 Patents (Medical) associated with Lisinopril

3,068

Literatures (Medical) associated with Lisinopril

01 Nov 2024·AMERICAN JOURNAL OF CARDIOLOGY

Prevention of Heart Failure in Hypertension—the Role of Coronary Heart Disease Events Treated With Versus Without Revascularization: The ALLHAT Study

Article

Author: Davis, Barry R ; Kapadia, Samir R. ; Kattan, Michael W ; Kattan, Michael W. ; Tereshchenko, Larisa G ; Chen, Vincent ; Kapadia, Samir R ; Davis, Barry R. ; Tereshchenko, Larisa G.

In modern clinical practice, less than half of patients with new-onset heart failure (HF) undergo ischemic evaluation and only a minority undergo revascularization. We aimed to assess the proportion of the effect of hypertension (antihypertensive treatment) on incident HF to be eliminated by prevention of coronary heart disease (CHD) event treated with or without revascularization, considering possible treatment-mediator interaction. The causal mediation analysis of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) included 42,418 participants (age 66.9 ± 7.7, 35.6% black, 53.2% men). A new CHD event (myocardial infarction or angina) that occurred after randomization but before the incident HF outcome was the mediator. Incident symptomatic congestive HF (CHF) and hospitalized/fatal HF (HHF) were the primary and secondary outcomes, respectively. Logistic regression (for mediator) and Cox proportional hazards regression (for outcome) were adjusted for demographics, cardiovascular disease history, and risk factors. During a median 4.5-year follow-up, 2,785 patients developed CHF, including 2,216 HHF events. Participants who developed CHD events had twice the higher incidence rate of CHF than CHD-free (28.5 vs 13.9 events/1,000 person-years). The proportion of reference interaction indicating direct harm because of a CHD event for lisinopril (234% for CHF, 355% for HHF) and amlodipine (244% for CHF, 468% for HHF) was greater than for chlortalidone (143% for CHF, 269% for HHF). In patients with revascularized CHD events, chlortalidone and amlodipine eliminated 21% to 24% and lisinopril eliminated -45% of HHF. Antihypertensive treatment could not eliminate harm from CHD events treated without revascularization. In conclusion, the antihypertensive drugs (chlortalidone, lisinopril, and amlodipine) prevent HF not principally by preventing CHD events but by way of other pathways. HF is moderated but not mediated by CHD events. Revascularization of CHD events is paramount for HF prevention.

01 Nov 2024·HYPERTENSION

Use and Cost Patterns of Antihypertensive Medications in the United States From 1996 to 2021

Article

Author: Hernandez, Inmaculada ; Cushman, William C. ; Whelton, Paul K. ; Bress, Adam P. ; King, Jordan B. ; Rodgers, Anthony ; Wang, Nelson ; Bellows, Brandon K. ; Jacobs, Joshua A. ; Zheutlin, Alexander R. ; Egan, Brent M. ; Derington, Catherine G.

BACKGROUND::

Antihypertensive medication use patterns have likely been influenced by changing costs and accessibility over the past 3 decades. This study examines the relationships between patent exclusivity loss, medication costs, and national health policies on antihypertensive medication use.

METHODS::

Using 1996 to 2021 Medical Expenditure Panel Survey data of US adults with hypertension taking at least 1 antihypertensive medication, we conducted a cross-sectional analysis. We explored the associations between patent exclusivity loss, per-pill costs, and Medicare Part D enactment on medication use over time, focusing on the most commonly used medications (lisinopril, amlodipine, losartan, hydrochlorothiazide, and metoprolol).

RESULTS::

The unweighted sample comprised 50 095 US adults (mean age, 62 years; 53% female). The survey-weighted number of adults taking antihypertensive medications increased from 22 million (95% CIs, 20–23 million) to 55 million (95% CI, 51–60 million) between 1996 and 2021. Loss of patent exclusivity led to increased medication fills, notably for lisinopril, amlodipine, and losartan, which all exhibited within-class dominance. However, per-pill cost decreases coinciding with Medicare Part D did not increase the number of individuals treated or the use of specific antihypertensive medications or classes.

CONCLUSIONS::

The increase in antihypertensive medication use over the past decades highlights the significant impact of loss of patent exclusivity on the uptake in the use of specific medications. These findings underscore the complexity of factors influencing medication use, beyond cost reductions alone, and suggest that policies need to consider multiple facets to effectively improve antihypertensive medication accessibility and utilization.

01 Nov 2024·SCIENCE OF THE TOTAL ENVIRONMENT

Bimetallic FeCu-MOF derivatives as heterogeneous catalysts with enhanced stability for electro-Fenton degradation of lisinopril

Article

Author: Padilla, José A ; Sirés, Ignasi ; Lanzalaco, Sonia ; Zhao, Lele ; Cabot, Pere L ; Murrieta, María F

A bimetallic FeCu/NC core-shell catalyst, consisting in nanoparticles where zero-valent Fe and Cu atoms, slightly oxidized on their surface, are encapsulated by carbon has been successfully prepared by modifying the synthesis route of MIL(Fe)-88B. FeCu/NC possessed well-balanced textural and electrochemical properties. According to voltammetric responses, in-situ Fe(III) reduction to Fe(II) by low-valent Cu was feasible, whereas the high double-layer capacitance confirmed the presence of a great number of electroactive sites that was essential for continuous H₂O₂ activation to ^•OH via Fenton's reaction. Electrochemical impedance and distribution of relaxation times (DRT) analysis informed about the strong leaching resistance of FeCu/NC. To validate the promising features of this catalyst, the advanced oxidation of the antihypertensive lisinopril (LSN) was investigated for the first time. The heterogeneous electro-Fenton (HEF) treatment of 16.1 mg L^-1 LSN solutions was carried out in a DSA/air-diffusion cell. At pH 3, complete degradation was achieved within 6 min using only 0.05 g L^-1 FeCu/NC; at near-neutral pH, 100 % removal was also feasible even in actual urban wastewater, requiring 60-75 min. The FeCu/NC catalyst demonstrated high stability, still maintaining 86.5 % of degradation efficiency after 5 cycles and undergoing low iron leaching. It outperformed the monometallic (Fe/NC and Cu/NC) catalysts, which is explained by the Cu(0)/Cu(I)-catalyzed Fe(II) regeneration mechanism that maintains the Fenton's cycle. LC-MS/MS analysis allowed the identification of two main primary LSN by-products. It can then be concluded that the FeCu/NC-based HEF process merits to be further scaled up for wastewater treatment.

News (Medical) associated with Lisinopril

14 Jun 2024

·www.globenewswire.com

Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut

• Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment of people living with acromegaly • Additional presentations provide insights into the validation of the Lipodystrophy Severity Scoring tool and the Chiesi Management of Acromegaly (MACRO) registry BOSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts. Presentations included a post hoc analysis of three Phase 3 clinical trials (CH-ACM-01, OPTIMAL, MPOWERED) studying MYCAPSSA (octreotide) as well as real-world MYCAPSSA use data from the Chiesi Management of Acromegaly (MACRO) registry and presentation of the Lipodystrophy Severity Scoring tool designed to assess the disease burden of lipodystrophy. "We're thrilled to support this community of people living with burdensome rare endocrine diseases through the innovation of new resources and validated medicines to aid in disease management," said Giacomo Chiesi, Head of Chiesi Global Rare Diseases. "As we approach the four-year anniversary of MYCAPSSA being on the market later this month, our commitment remains steadfast to commercializing solutions for the acromegaly and lipodystrophy patient communities.” Oral PresentationTitle: Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials2Key Highlights: MYCAPSSA demonstrated a 72% response rate in patients entering the studies with IGF-I values of ≤ 1x the upper limit of normal. A patient’s prior dose level of injectable medication did not significantly impact response rates.In this post-hoc analysis, symptom improvement was notable with significant reductions in joint pain (36% to 22%) and swelling (15% to 10%) in patients responding to MYCAPSSA. Median decrease of one symptom per patient and a mean decrease of 0.8 in Acromegaly Index of Severity (AIS) further underscored symptom improvement.Safety analysis revealed gastrointestinal issues as the most common adverse events with a median duration and time to onset of roughly two weeks for the first occurrence and a low rate of discontinuation. Late-Breaker Poster PresentationsTitle: Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience3Key Highlights: Of the 230 patients participating in Chiesi Management of Acromegaly (MACRO) registry, 32 (14%) received MYCAPSSA at baseline, with an additional 26 (11%) initiating post-baseline. Common reasons for initiation included patient preference and lack of symptom or biochemical control.The mean time on OOC was 19.7 months, with the majority receiving treatment for at least 6 months. Most patients remained well-controlled biochemically and symptomatically, with 87% biochemically controlled and 71% symptomatically controlled at the last follow-up.The discontinuation rate was 33% and in cases attributed to a lack of biochemical or symptom control, dose titration to 80mg/day was not implemented in many cases.Overall, OOC demonstrated efficacy in maintaining or achieving biochemical control with the majority of newly-initiated patients reporting well-controlled symptoms. Title: Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy4Key Highlights: The lipodystrophy severity score (LDS) is a validated tool that captures severity in patients with diverse manifestations of lipodystrophy. The LDS allows comparisons among patient groups and changes within patients over time.The LDS is a tool designed to quantify the diverse complications of lipodystrophy, a group of rare, potentially life-threatening disorders that affect how the body accumulates and stores fat.The LDSs showed high reliability and strong correlation with the Clinical Global Impression (CGI) of severity, effectively capturing the severity of lipodystrophy and changes over time. This tool is intended to compare patient groups, and monitor individual progress with future analysis involving in real-world data sets.Development into an online platform enhances functionality – a versatile and valuable resource for the lipodystrophy community.Future work will assess the LDS using real-world datasets. MYCAPSSA IMPORTANT SAFETY INFORAMATION INDICATION AND USAGE MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. CONTRAINDICATIONS Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide. IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS MYCAPSSA can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted. ADVERSE REACTIONS The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis. DRUG INTERACTIONS The following drugs require monitoring and possible dose adjustment when used with MYCAPSSA: cyclosporine, insulin, antidiabetic drugs, calcium channel blockers, beta blockers, lisinopril, digoxin, bromocriptine, and drugs mainly metabolized by CYP3A4. Counsel women taking an oral contraceptive to use an alternative non-hormonal method of contraception or a back-up method when taking MYCAPSSA. Patients taking proton pump inhibitors, H2-receptor antagonists, or antacids concomitantly with MYCAPSSA may require increased dosages of MYCAPSSA. PREGNANCY Advise premenopausal females of the potential for an unintended pregnancy. Please contact Chiesi Farmaceutici S.p.A. at 1-888-661-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. About AcromegalyAcromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision, and enlargement of the hands, feet, tongue, and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders, and cardiac and cerebrovascular disease. Acromegaly affects over 25,000 people in the United States alone with roughly 8,000 being treated with injectable somatostatin receptor ligands (iSRLs). A significant percentage of these people experience burdens associated with receiving iSRLs including prolonged injection-related pain and poorly-controlled symptoms. About LipodystrophyLipodystrophy syndromes are a heterogeneous group of rare, potentially life-threatening disorders that affect how the body accumulates and stores fat. These syndromes are categorized into two main forms: generalized lipodystrophy, characterized by the near-complete absence or progressive loss of fat (adipose) tissue, and partial lipodystrophy, where the tissue loss is more limited, typically impacting areas like limbs or upper body. Lipodystrophy is also categorized by etiology with inherited and acquired forms1. About Chiesi Global Rare DiseasesChiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com. About Chiesi GroupChiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we’re part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit www.chiesi.com Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004 Mar 18;350(12):1220-34. Doi: 10.1056/NEJMra025261. PMID: 15028826.Fleseriu M, et al. Biochemical Response, Symptom Control, and Safety of Oral Octreotide Capsules Treatment in Acromegaly: A Post Hoc Analysis of a Large Pooled Database from Three Phase 3 Clinical Trials. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts.Yuen K, et al. Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts.Brown R, et al. Lipodystrophy Severity Score: Validation Of A Tool To Assess Disease Burden In Lipodystrophy. Presented at: Endocrine Society’s ENDO 2024 Meeting; June 1-4, 2024; Boston, Massachusetts. Chiesi Group Media ContactChiara TravaginRare Communication ManagerTel: +39 348 8818985Email c.travagin@chiesi.com Sky Striar LifeSci CommunicationsTel: 617-797-6672Email sstriar@lifescicomms.com

Clinical ResultPhase 3

06 Jun 2024

·www.drugs.com

Several Drugs Linked to Risk for Aneurysmal Subarachnoid Hemorrhage

THURSDAY, June 6, 2024 -- Several commonly prescribed drugs are associated with aneurysmal subarachnoid hemorrhage (aSAH), according to a study published online June 5 in Neurology . Jos P. Kanning, from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a drug-wide association study to examine the association between commonly prescribed drugs and aSAH incidence. Use of commonly prescribed drugs was examined across exposure windows (current, within three months; recent, three to 12 months; and past, >12 months). Exposure to 205 commonly prescribed drugs was investigated among 4,879 aSAH cases and 43,911 matched controls. The researchers found similar trends for lisinopril and amlodipine, with a decreased risk for aSAH in association with current use, while the risk for aSAH was increased with recent use. The risk for aSAH was reduced with current use of simvastatin, metformin, and tamsulosin. Increased aSAH risk was seen in association with current use of warfarin, venlafaxine, prochlorperazine, and co-codamol. "Future research should use a more hypothesis-driven approach to further investigate these associations and differentiate between drug class and specific drug substance effects," the authors write. "In addition, this research may help identify additional risk factors for aSAH, potentially leading to new pharmacologic therapy options for aneurysmal management." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

05 Jun 2024

·www.sciencedaily.com

Could taking certain drugs reduce risk of ruptured brain aneurysm?

A new study suggests that people who take a few common drugs may have a decreased risk of having a bleeding stroke due to a ruptured brain aneurysm. The results do not prove that these drugs reduce the risk of this type of aneurysm; they only show an association. A new study suggests that people who take a few common drugs may have a decreased risk of having a bleeding stroke due to a ruptured brain aneurysm. The study is published in the June 5, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. The results do not prove that these drugs reduce the risk of this type of aneurysm; they only show an association. "We urgently need new ways to prevent this type of stroke, which occurs at younger ages and with a higher death rate than other types of stroke," said study author Jos Peter Kanning, MSc, of University Medical Center Utrecht in the Netherlands. "Our current surgical treatments for brain aneurysms have a risk of permanent disability and death that often outweighs the potential benefits, so preventing rupture with a non-invasive drug would be very beneficial." For the study, researchers looked at 4,879 people who had ruptured brain aneurysms, called aneurysmal subarachnoid hemorrhages. Those people were each compared to nine people of the same age and sex, for a total of 43,911 people who did not have ruptured brain aneurysms. Then researchers looked at electronic health records to see what prescription drugs people took. They found that four drugs were associated with a decreased risk of having a ruptured brain aneurysm: the high blood pressure drug lisinopril; the cholesterol drug simvastatin; the diabetes drug metformin; and the drug tamsulosin, prescribed for enlarged prostate. After adjusting for other factors that could affect the risk of stroke, such as high blood pressure, smoking, alcohol abuse and total number of other health conditions, researchers found that people currently taking lisinopril were 37% less likely to have a ruptured brain aneurysm than those not taking the drug. People taking simvastatin were 22% less likely to have a stroke. Those taking metformin were 42% less likely to have a stroke and those taking tamsulosin were 45% less likely. Researchers also found an increased risk of having a ruptured brain aneurysm for people taking four drugs: the blood thinner warfarin; the antidepressant venlafaxine; the antipsychotic and antiemetic drug prochlorperazine; and the painkiller co-codamol. "Future research is needed to investigate these associations and determine whether these drugs are effective in reducing the risk of hemorrhagic stroke," Kanning said. "This work could also help us identify additional risk factors for subarachnoid hemorrhage, potentially leading to new therapies to manage aneurysms." A limitation of the study was that researchers looked at drug prescriptions. It is possible that people may not take their drugs or may take them incorrectly. The study was supported by the European Research Council.

Clinical Result

100 Deals associated with Lisinopril

External Link

KEGG	Wiki	ATC	Drug Bank
D08131	Lisinopril	C09AA03	DB00722

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Chronic heart failure	JP	Kyowa Pharmaceutical Industry Co., Ltd.	30 Jun 1995
Essential Hypertension	CH	Atnahs Pharma UK Ltd.	08 May 1989
Hypertension, Renovascular	CH	Atnahs Pharma UK Ltd.	08 May 1989
Acute myocardial infarction	US	Merck Research Laboratories Massachusetts LLC	29 Dec 1987
Heart Failure	US	Merck Research Laboratories Massachusetts LLC	29 Dec 1987
Hypertension	US	Merck Research Laboratories Massachusetts LLC	29 Dec 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Polycystic Kidney, Autosomal Dominant	Phase 3	US	Alvogen, Inc.	09 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00430040 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Inflammation \| Hypertension ... View more	14	lisinopril+Carvedilol Controlled Release (CR) (Carvedilol)	zglervdofp(ibgwvyzsnh) = utdzghkkul cbrpjdxkbr (kftwvkchpj, hlgmllafgo - eoleiwgpje) View more	-	16 Apr 2024
				lisinopril (Lisinopril)	zglervdofp(ibgwvyzsnh) = ojmihgzwcb cbrpjdxkbr (kftwvkchpj, ikknahtmtn - kydvtvadak) View more
NCT03461003 (NICHE, CTgov)	Phase 4	Hypertension	49	Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	wsyxtolmoq(arwhijhuun) = kezlihhaxs jrpmnygixh (ffkpxlerov, vuqwaeygbe - jdiploxrdk) View more	-	09 Sep 2022
				Usual care (Usual Care)	wsyxtolmoq(arwhijhuun) = ylqfndeijh jrpmnygixh (ffkpxlerov, qdqcsrfyky - uqvfxejqbq) View more
NCT01009918 (Lisinopril or Coreg CR in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab, CTgov)	Phase 2	Cardiotoxicity \| Breast Cancer	468	lisinopril (Arm I Lisinopril)	mkkxmwmttq(wsygclugwi) = aqugajobrx ppwoplvluv (ujamqvleke, xvzvbmjwiw - cyhrmcyhzh) View more	-	30 Mar 2021
				Coreg CR® (Arm II Coreg CR®)	mkkxmwmttq(wsygclugwi) = wouvpqdsxl ppwoplvluv (ujamqvleke, iregfmekvi - fmlizhmtxr) View more
NCT01984164 (CALIBREX, CTgov)	Phase 2	Mild cognitive disorder \| Hypertension	176	Candesartan (Candesartan)	bydndhusgd(uaqznzepja) = gdvhkzbjft nzfrtspkuf (btuvwjxnzf, ufcfsocfkc - aqshipfnlp) View more	-	21 Feb 2021
				Lisinopril (Lisinopril)	bydndhusgd(uaqznzepja) = bvvrdclnxc nzfrtspkuf (btuvwjxnzf, nnadktysns - hvqgkvbvzu) View more
ASN2020	Not Applicable	Hypertension	-	Lisinopril 20 mg	wefabiskfq(cxldcpfohh) = frcfiuetdf uarvjyfykg (kdsquupxiy )	Positive	19 Oct 2020
				Ca channel blocker	wefabiskfq(cxldcpfohh) = qiarnzrygn uarvjyfykg (kdsquupxiy )
NCT00874432 (CTgov)	Phase 2	Cardiovascular Diseases \| Stiffness \| Chronic Kidney Diseases	43	angiotensin converting enzyme inhibitor (Chronic Kidney Disease)	neajovcnke(udnusspcxb) = vqssxejoxc iztiuqtson (ghgvxfckke, ieppcfbokn - bmfaaawczx) View more	-	23 Sep 2020
				angiotensin converting enzyme inhibitor (Age Matched Control)	neajovcnke(udnusspcxb) = mzaevjifkh iztiuqtson (ghgvxfckke, qddupbdymi - wnuaczijze) View more
NCT00673790 (CTgov)	Phase 4	Glucose Intolerance \| Hypertension	537	lisinopril+Nebivolol+losartan (Nebivolol)	iylqptizsj(ckggwgauws) = zjfxeehnfw urkgkwbifu (tyrytorjua, fzwzkqukic - kbomwjmhti) View more	-	26 Feb 2020
				lisinopril+losartan (Placebo)	iylqptizsj(ckggwgauws) = ibvoddghev urkgkwbifu (tyrytorjua, xgwvqaxeso - ywixkakdbu) View more
NCT01880528 (CTgov)	Phase 2	Dyspnea \| Small Cell Lung Cancer \| Non-Small Cell Lung Cancer	23	lisinopril (Arm I (Lisinopril))	yvhdkvlxbz(qhzkpiyoie) = ernatrjzux azbonistfk (sypztconav, upnidpmvzb - gqckhdmpbu) View more	-	17 Sep 2019
				placebo (Arm II (Placebo))	yvhdkvlxbz(qhzkpiyoie) = qdbdthkhbh azbonistfk (sypztconav, ndqbjzzibo - ovzpvhlbny) View more
AAIC2019	Not Applicable	-	16	Lisinopril (treatment group)	uytewlwamq(qlsegtscrl) = udvljdhask uuqnfokeqv (ewjbspyttf )	-	01 Jul 2019
				LISINOPRIL (Control group)	uytewlwamq(qlsegtscrl) = bkpqagdxix uuqnfokeqv (ewjbspyttf )
ESC2018	Not Applicable	Chronic heart failure First line	-	Enalapril	ptlzhbbzsh(eckbghofzr) = elqrrqmiqe npfrtuzbxd (lvjjxnqajx )	-	26 May 2018
				Lisinopril	ptlzhbbzsh(eckbghofzr) = hiemnygirw npfrtuzbxd (lvjjxnqajx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis